HIF PHD2 Antibodies

Santa Cruz Biotechnology features a diverse variety of HIF PHD2 monoclonal antibodies for research in hypoxia signaling and cellular response mechanisms. HIF PHD2 Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). HIF PHD2, or hypoxia-inducible factor prolyl hydroxylase domain 2, plays a central role in regulating the hypoxia-inducible factor (HIF) pathway, which is essential for cellular adaptation to low oxygen levels. By hydroxylating specific proline residues on HIF, HIF PHD2 modulates HIF stability and activity, influencing processes such as angiogenesis, metabolism, and cell survival. Understanding HIF PHD2 function is crucial for elucidating implications in various diseases, including cancer and ischemic conditions. Researchers can explore the complex interactions between HIF PHD2 and other cellular components through detailed molecular analyses. Advanced visualization techniques using conjugated secondary antibodies, including horseradish peroxidase (HRP), phycoerythrin (PE), and fluorescein isothiocyanate (FITC), enable precise detection and localization of HIF PHD2. Investigating HIF PHD2's role in oxygen sensing mechanisms provides valuable insights into cellular stress responses and adaptation pathways. Santa Cruz Biotechnology monoclonal antibodies for HIF PHD2 support researchers worldwide in advancing our understanding of hypoxia-related cellular processes and potential therapeutic interventions.